Zobrazeno 1 - 10
of 45
pro vyhledávání: '"pharmacoeconomic modeling"'
Autor:
Sergey V. Nedogoda, Marina V. Zhuravleva, Sergey N. Tereshchenko, Alla S. Salasyuk, Igor V. Zhirov, Irina N. Barykina, Viktoria O. Lutova, Ekaterina A. Popova
Publikováno v:
Терапевтический архив, Vol 96, Iss 8, Pp 771-779 (2024)
Aim. To evaluate the clinical and economic effectiveness of dapagliflozin in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (HFrEF) in the Russian Federation in various subgroups of standard therapy for CHF.
Externí odkaz:
https://doaj.org/article/3fd97e36a00640bfba4c78ac473e450d
Publikováno v:
Фармакоэкономика, Vol 16, Iss 4, Pp 527-536 (2024)
Objective: to evaluate the clinical and economic effectiveness of benralizumab in comparison with standard therapy in patients with severe bronchial asthma (SBA) with an eosinophilic phenotype in the Russian Federation.Material and methods. A clinica
Externí odkaz:
https://doaj.org/article/202ddd6e43c44c1fb5bc1fe93988acc6
Autor:
Sergey V. Nedogoda, Minara S. Shamkhalova, Alla S. Salasyuk, Viktoriya O. Lutova, Irina N. Barykina, Ekaterina A. Popova
Publikováno v:
Клинический разбор в общей медицине, Vol 3 , Iss 2, Pp 33-43 (2024)
Background. The economic costs associated with chronic kidney disease (CKD) are a significant burden on the health care system. The use of dapagliflozin is a breakthrough strategy in the management of patients with CKD and type 2 diabetes mellitus (T
Externí odkaz:
https://doaj.org/article/06239df5d0494751b81ecbd87a40385e
Autor:
Sergey V. Nedogoda, Sergey N. Tereshchenko, Igor V. Zhirov, Alla S. Salasyuk, Irina N. Barykina, Viktoria O. Lutova, Ekaterina A. Popova
Publikováno v:
Терапевтический архив, Vol 95, Iss 9, Pp 782-788 (2023)
Aim. To estimate the cost-effectiveness of dapagliflozin across the range of ejection fraction in patients with heart failure (HF) in Russian Federation. Materials and methods. Cost-effectiveness model was developed for estimate the use of dapagli
Externí odkaz:
https://doaj.org/article/5cdd37a6c334452eaa1cd66c41c48798
Autor:
Sergey V. Nedogoda, Alla S. Salasyuk, Irina N. Barykina, Viktoria O. Smirnova, Ekaterina A. Popova
Publikováno v:
Consilium Medicum, Vol 23, Iss 12, Pp 932-938 (2021)
Aim. To evaluate the clinical and economic efficiency of the use of dapagliflozin in patients with chronic kidney disease (CKD) stages 24 in Russian Federation. Materials and methods. Cost-effectiveness (utility) analysis has been carried out. Mat
Externí odkaz:
https://doaj.org/article/b9992e3ad34c40bbb6a68a407c78ccd3
Publikováno v:
Фармакоэкономика, Vol 13, Iss 2, Pp 101-111 (2020)
Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pul
Externí odkaz:
https://doaj.org/article/8fb52a2ddbde4e21bc5cee65b83d1275
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 12, Pp 307-315 (2020)
Mehmet Berktas,1 Feza Kirbiyik,2 Elif Aribal,2 Anil Aksit,2 Derya Ufuk Altintas3 1Blue Idea Consulting, London, UK; 2Nutricia Advanced Medical Nutrition, Istanbul, Turkey; 3Cukurova University Medical School, Allergy and Immunology Department, Adana,
Externí odkaz:
https://doaj.org/article/bd6667650dbc4b6cb5bf38a6408cff1e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Medical Care, 2004 Apr 01. 42(4), 39-44.
Externí odkaz:
https://www.jstor.org/stable/4640762
Autor:
N. K. Mazina, P. V. Mazin
Publikováno v:
Фармакоэкономика, Vol 10, Iss 3, Pp 12-21 (2017)
Recently, an increase in the incidence of severe forms of prostate cancer, in particular castration-resistant prostate cancer (CRPC) has been noticed. Treatment of CRPC patients is associated with increasing expenses and thus impacts the healthcare b
Externí odkaz:
https://doaj.org/article/f104d0ca42184d868a371f3c5c52ee4f